StockTipsArenaBeta

BUY Shilpa Medicare Limited — Kunal Hasmukhlal Shah

BUYShilpa Medicare Limited

byKunal Hasmukhlal ShahHorizon: 1–3 months1 Sept 2026via NDTV Profit

Entry₹877.45Inferred
Target₹950
Total upside +8.27% (call closed)
Stop lossNot given
Exit₹9501 Sept 2026, 2:09 pm
Target hit+8.27%0.00%upside left
Follow Kunal Hasmukhlal Shah for new calls(75% target hit, 12 closed calls)Get alertsWatch SHILPAMED for new buy/sell callsGet alertsSee 16 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 1 Sept 2026
1 supporting4 neutral2 opposing
Supports the BUY call (1)

Shilpa Medicare Q1 Results: Highest quarterly revenue and EBITDA on record sends stock 17% higher

NewsCnbc-Tv18·5 Aug · 4w ago

(opens in new tab)
Neutral / worth noting (4)

Shilpa Medicare recalls 27,923 chemotherapy drug vials in US over discolouration

NewsCnbc-Tv18·18 Aug · 2w ago

(opens in new tab)

Q1 Results Today Highlights: Godrej Agrovet posts mixed Q1; Whirlpool PAT falls 34%, Berger Paints, Biocon, Shilpa Medicare, Aster DM, Navin Fluorine report profit growth

NewsHbl·5 Aug · 4w ago

(opens in new tab)

Shilpa Medicare Limited has submitted to the Exchange, the Unaudited standalone and consolidated financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · 4w ago

(opens in new tab)

Unaudited Financial Results for the Quarter ended 30 June 2026

BSE · Board Meeting·5 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (2)

Shilpa Medicare Limited Initiates Recall of Pemrydi Rtu (Pemetrexed Injection) Due to Discolored Solution

NewsGoogle News·29 Aug · 3d ago

(opens in new tab)

Shilpa Medicare Recalls Over 27,000 Chemotherapy Vials In US After Discolouration Reports

NewsNdtv-Profit·18 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.